Skip to content

Light Therapy for Obsessive-compulsive Disorder (OCD)

A Circadian Medicine Light-based Intervention for Obsessive-compulsive Disorder (OCD)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05391503
Enrollment
21
Registered
2022-05-26
Start date
2022-09-23
Completion date
2024-08-31
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-Compulsive Disorder

Keywords

circadian, sleep, anxiety, OCD

Brief summary

The purpose of this study is to examine the effect of a light-based circadian treatment on OCD symptoms in adults with OCD and late bedtimes. This study will have important implications for understanding the role of circadian rhythms in the etiology and treatment of OCD.

Detailed description

Prior to the start of this study, there are screening procedures to ensure participants meet the criteria for the study. At the first consent screening appointment, participants will learn more about the study and answer questionnaires. All of the results of the screening procedures are confidential and will only be used by the study staff to determine eligibility for the study. This study is 5 weeks long and involves 4 in-person lab visits at the Sleep and Chronobiology Lab. Participants will be randomly assigned to either an active or placebo light therapy treatment condition. Visit 1 will involve additional screening to determine eligibility, including questionnaires and interviews. If eligible, participants will then track their sleep for 2 weeks at home with a wrist-worn activity monitor and a sleep diary. Visit 2 will take place in the lab from 5:30pm until 1 hour after participants typical bedtime. The investigators will ask participants to provide saliva samples hourly to measure melatonin and complete questionnaires. The investigators will provide treatment instructions at this visit. Investigators will then ask participants to engage in the treatment at home for 3 weeks. Investigators will schedule 1 in-person visit (Visit 3) and 1 phone call to assess adherence to the treatment during these 3 weeks. Visit 4 will take place in the lab after the treatment is finished. Visit 4 will last from 5:30pm until 1.5 hours after participants typical bedtime and will involve hourly saliva samples to measure melatonin, questionnaires, and interviews.

Interventions

BEHAVIORALLight therapy

Morning bright light for 60 minutes after awakening

Placebo morning bright light for 60 minutes after awakening

Sponsors

University of Colorado, Boulder
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Primary OCD diagnosis (according to the Diagnostic and Statistical Manual of Mental Disorders 5) * Bedtime 0100 or later * Age 18-35 * English speaking

Exclusion criteria

* Subjects must not be currently participating in another research study that would influence their participation in our study. * Past 6-month substance use disorder * Lifetime psychosis or bipolar disorder * Current sleep disorder (DSWPD and insomnia excepted) * Significant, active suicidal ideation or behaviors in the past 6 months * Intellectual disability * Engaged in evidence-based psychotherapy for OCD * History of light therapy or cognitive behavior therapy for insomnia * Night shift work or travel outside of Mountain Standard Time in the past month * Pregnant, trying to become pregnant, or breastfeeding * Change in psychotropic medication in the past month * Prescribed or over the counter sleep medication use in the past month * Beta-block or monoamine oxidase inhibitor use in the past month

Design outcomes

Primary

MeasureTime frameDescription
Obsessive-Compulsive Inventory-Revised score3 weeksSelf-reported OCD symptoms. Minimum score=0, maximum score=74. Higher scores indicate worse outcome

Secondary

MeasureTime frameDescription
Yale-Brown Obsessive-Compulsive Scale score5 weeksInterviewer-assessed OCD symptoms. Minimum score=0, maximum score=40. Higher scores indicate worse outcome

Other

MeasureTime frameDescription
Circadian phase3 weeksCircadian phase assessed by dim light melatonin onset (DLMO)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026